Appointments at Penn Pharma, Almac and Beardsworth – People on the move

Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Penn Pharma, Almac and Beardsworth.

Patheon has hired Michael Lytton as executive vice president (EVP), corporate development and strategy, and general counsel. Lytton last worked at Biogen Idec and practiced law for 17 years.

Alison Martin has been named VP, international projects at Synexus. Martin joins from INC Research where she worked as VP, clinical development, cardiovascular and endocrine.

Penn Pharma has appointed Mark Dean-Netscher as chief operating officer. Dean-Netscher has previously worked at Catalent Pharma Solutions and Reckitt Benckiser.

Todd Kole has joined Almac Clinical Technologies as vice president of clinical project services. Kole spent the past 12 years working at Clinphone and Perceptive Informatics.

Beardsworth has made two appointments to strengthen its oncology team. Evette Riegel, formerly of Quintiles and Wyeth, has been promoted to senior director, clinical operations and project management.

Also, Saishree Ramalingam joins the company as senior project manager. Ramalingam has previously worked at Pfizer, PharmaNet, Celgene, PRA International and more.

Cambridge Major Laboratories (CML) has named Richard Proehl as VP of manufacturing. Proehl last worked at Coviden where he was responsible for the company’s largest active pharmaceutical ingredient (API) production plant.

Mark Wilkinson, EVP and chief information officer at PPD, has been appointed to serve on the USS North Carolina Battleship Commission by State Governor Beverly Perdue. Wilkinson worked in the US military for 23 years and will now oversee the exhibit for World War II veterans.

BASi (Bioanalytical Systems Inc) has made two hires. Peter White, formerly of AstraZeneca, is the new director of laboratory operations. Also, Bhavna Mistry has joined as senior scientist and principal investigator. Mistry also last worked at AstraZeneca.